AR074159A1 - Una sal de glicinato de metformina para el control de glucosa en la sangre, proceso para su obtencion y su uso - Google Patents
Una sal de glicinato de metformina para el control de glucosa en la sangre, proceso para su obtencion y su usoInfo
- Publication number
- AR074159A1 AR074159A1 ARP090102388A ARP090102388A AR074159A1 AR 074159 A1 AR074159 A1 AR 074159A1 AR P090102388 A ARP090102388 A AR P090102388A AR P090102388 A ARP090102388 A AR P090102388A AR 074159 A1 AR074159 A1 AR 074159A1
- Authority
- AR
- Argentina
- Prior art keywords
- metformin
- salt
- glycinate
- glycine
- hydrochloride
- Prior art date
Links
- KOFRCHIVYXPUNL-UHFFFAOYSA-N 2-aminoacetic acid;3-(diaminomethylidene)-1,1-dimethylguanidine Chemical class NCC(O)=O.CN(C)C(=N)N=C(N)N KOFRCHIVYXPUNL-UHFFFAOYSA-N 0.000 title abstract 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 4
- 239000008280 blood Substances 0.000 title abstract 4
- 210000004369 blood Anatomy 0.000 title abstract 4
- 239000008103 glucose Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 10
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical class CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 7
- 239000004471 Glycine Substances 0.000 abstract 5
- 229960003105 metformin Drugs 0.000 abstract 4
- 239000002244 precipitate Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 239000012736 aqueous medium Substances 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 2
- 238000005342 ion exchange Methods 0.000 abstract 2
- 229950007228 metformin glycinate Drugs 0.000 abstract 2
- 229960004329 metformin hydrochloride Drugs 0.000 abstract 2
- 239000000047 product Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 238000003756 stirring Methods 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- -1 1,1-dimethylbiguanid glycinate salt Chemical class 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical class NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 238000007912 intraperitoneal administration Methods 0.000 abstract 1
- 238000010253 intravenous injection Methods 0.000 abstract 1
- 239000002609 medium Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente se refiere a la síntesis de una sal de Glicinato 1,1-dimetilbiguanid, llamada Glicinato de Metformina disenada para el control de la glucosa en sangre. Estas sal exhibe ventajas sobre otras sales de metformina. Estas ventajas se refieren, en primer lugar, al hecho de que el contraion exhibe efectos hipoglucemientes por sí mismos, el efecto hipoglucemiente es más pronunciado. Además esta sal exhibe una mejor absorcion, alcanzando una concentracion plasmática más alta que aquella producida con clorhidrato de metformina. La síntesis se llevo a cabo a partir de clorhidrato de metformina liberando el contraion hidrocloruro, usando una columna de intercambio ionico, la metformina liberada se disolvio en medio acuoso y subsecuentemente se adiciono glicina a temperatura ambiente y agitacion constante, el producto resultante se calienta produciendo una solucion concentrada del producto, se adiciona un solvente orgánico para crear insolubilidad y favorecer la cristalizacion en un medio saturado, el exceso de glicina precipita y se obtiene la sal glicinato de metformina después de filtrar y concentrar dicha sal. La sal Glicinato de Metformina presenta un efecto farmacologico más pronunciado en la reduccion de los niveles de glucosa en sangre. Reivindicacion 6: Un procedimiento para obtener la sal de metformina y glicinato que se caracteriza por comprender las siguientes etapas: se hace pasar una solucion de la sal clorhidrato de metformina por una columna de intercambio ionico para obtener la metformina libre separando el contraion clorhidrato; la metformina liberada se disuelve en medio acuoso y se le adiciona glicina a temperatura ambiente agitando continuamente; se concentra la mezcla resultante y se agrega un disolvente donde la glicina sea insoluble, hasta conseguir que el exceso de esta precipite; se filtra para eliminar el exceso de glicina y al resultado se evapora hasta conseguir un segundo precipitado; y se lava y se purifica el segundo precipitado. Reivindicacion 7: El uso de la sal de la reivindicacion 1 para tratar la hiperglicemia en animales de sangre caliente caracterizada porque consiste en administrar diversas dosis de glicinato de metformina por diversas vías: inyectable intravenosa, inyectable intramuscular, nasal, intraperitoneal, sublingual, etc., pero preferentemente oral para lograr una disminucion de los niveles de glucosa en la sangre.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2008/002665 WO2009144527A1 (en) | 2008-06-26 | 2008-06-26 | A new metformin glycinate salt for blood glucose control |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074159A1 true AR074159A1 (es) | 2010-12-29 |
Family
ID=40383805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102388A AR074159A1 (es) | 2008-06-26 | 2009-06-26 | Una sal de glicinato de metformina para el control de glucosa en la sangre, proceso para su obtencion y su uso |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8703183B2 (es) |
| EP (1) | EP2303838B1 (es) |
| JP (1) | JP5551691B2 (es) |
| KR (1) | KR101522066B1 (es) |
| CN (1) | CN102159539B (es) |
| AR (1) | AR074159A1 (es) |
| AU (1) | AU2008357111B2 (es) |
| BR (1) | BRPI0822909B8 (es) |
| CA (1) | CA2729035C (es) |
| CL (1) | CL2009001484A1 (es) |
| CY (1) | CY1115098T1 (es) |
| DK (1) | DK2303838T3 (es) |
| EC (1) | ECSP10010719A (es) |
| ES (1) | ES2450148T3 (es) |
| HR (1) | HRP20140194T1 (es) |
| JO (1) | JO2884B1 (es) |
| MA (1) | MA32418B1 (es) |
| MX (1) | MX2011000135A (es) |
| NI (1) | NI201000234A (es) |
| PE (1) | PE20100257A1 (es) |
| PL (1) | PL2303838T3 (es) |
| PT (1) | PT2303838E (es) |
| SI (1) | SI2303838T1 (es) |
| TN (2) | TN2010000604A1 (es) |
| UY (1) | UY31945A (es) |
| WO (1) | WO2009144527A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2303838T1 (sl) | 2008-06-26 | 2014-07-31 | Laboratorios Silanes, S.A. De C.V. | Nova sol metformin glicinata za nadzor glukoze v krvi |
| US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
| US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| CN103263405B (zh) * | 2013-05-08 | 2015-04-22 | 南京医科大学 | 用于治疗糖尿病的药物组合物及其应用 |
| US9815777B2 (en) | 2013-09-22 | 2017-11-14 | Jiva Pharma, Inc. | Metformin salts to treat Type2 diabetes |
| US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| US9505709B2 (en) | 2014-05-05 | 2016-11-29 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
| WO2015183794A1 (en) * | 2014-05-27 | 2015-12-03 | City Of Hope | Tgr5 agonist complexes for treating diabetes and cancer |
| US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
| MX2016016830A (es) | 2014-06-18 | 2017-07-07 | Thetis Pharmaceuticals Llc | Complejos de aminoacidos minerales de agentes activos. |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| EP3933845A3 (en) | 2014-10-27 | 2022-06-22 | Aseko, Inc. | Subcutaneous outpatient management |
| CN105030745A (zh) * | 2015-07-08 | 2015-11-11 | 南京医科大学 | 甘氨酸和二甲双胍的酰胺化产物在制备治疗糖尿病药物中的应用 |
| EP3337402B1 (en) | 2015-08-20 | 2026-01-07 | Glytec, LLC | Diabetes management therapy advisor |
| DK3454907T3 (da) | 2016-06-03 | 2020-10-19 | Thetis Pharmaceuticals Llc | Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation |
| WO2018060959A1 (en) * | 2016-09-30 | 2018-04-05 | Laboratorios Silanes S.A. De C.V. | Metformin glycinate, pharmaceutical compositions comprising the same, and methods of using the same |
| US11510886B2 (en) | 2016-09-30 | 2022-11-29 | Laboratorios Silanes, S.A. De C.V. | Metformin amino acid compounds and methods of using the same |
| CN113105367B (zh) | 2021-03-30 | 2022-08-02 | 广州大学 | 一类二甲双胍盐及其制备方法和应用 |
| CN114349665B (zh) * | 2021-11-30 | 2023-06-09 | 潍坊博创国际生物医药研究院 | 二甲双胍焦谷氨酸晶体及其制备方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE568513A (es) | ||||
| FR2037002A1 (en) | 1969-04-30 | 1970-12-31 | Roques Bernard | N-substd biguanide pamoic acid salts prepn |
| DE1967138A1 (de) | 1969-07-17 | 1977-11-10 | Christian Brunnengraeber Chem | Therapeutisches mittel |
| AT325632B (de) | 1973-06-01 | 1975-10-27 | Hurka Wilhelm | Verfahren zur herstellung von nicotinsauren salzen von derivaten des biguanids |
| FR2243684B1 (es) | 1973-09-19 | 1977-01-28 | Semb | |
| CH602612A5 (es) | 1974-10-11 | 1978-07-31 | Hoffmann La Roche | |
| FR2320735A1 (fr) | 1975-08-12 | 1977-03-11 | Dabis Georges | Composition anti-cellulite |
| JPS57179494A (en) | 1981-04-30 | 1982-11-05 | Mitsubishi Plastics Ind | Method of closing through hole of pipe, circumferential wall thereof has through hole in pipe axial direction |
| FR2585572B3 (fr) | 1985-07-31 | 1987-12-31 | Hugelin Andre | Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse |
| DE793646T1 (de) * | 1994-11-23 | 1999-12-30 | Pharmacia & Upjohn Co., Kalamazoo | Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus |
| CA2312990C (en) | 1997-12-08 | 2008-04-29 | Bristol-Myers Squibb Company | Novel salts of metformin and method |
| US6936275B2 (en) | 1999-12-20 | 2005-08-30 | Scolr, Inc. | Amino acid modulated extended release dosage form |
| WO2003068209A1 (en) * | 2002-02-14 | 2003-08-21 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
| US7181457B2 (en) * | 2003-05-28 | 2007-02-20 | Pervasive Software, Inc. | System and method for utilizing compression in database caches to facilitate access to database information |
| CA2543945A1 (en) | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid |
| WO2005065675A1 (en) * | 2004-01-07 | 2005-07-21 | Premacs International Pty. Ltd. | Method of treatment |
| WO2006086856A1 (en) | 2005-02-15 | 2006-08-24 | Messadek, Jallal | Combination therapeutic compositions and method of use |
| CN101180073A (zh) * | 2005-04-27 | 2008-05-14 | 贾拉尔·梅萨德克 | 胰岛素组合 |
| WO2007149313A1 (en) * | 2006-06-16 | 2007-12-27 | Indigene Pharmaceuticals Inc. | Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications |
| NZ556735A (en) * | 2007-07-24 | 2009-03-31 | Vector Ltd | Securing devices and equipotential bonding system |
| SI2303838T1 (sl) | 2008-06-26 | 2014-07-31 | Laboratorios Silanes, S.A. De C.V. | Nova sol metformin glicinata za nadzor glukoze v krvi |
-
2008
- 2008-06-26 SI SI200831163T patent/SI2303838T1/sl unknown
- 2008-06-26 JP JP2011515639A patent/JP5551691B2/ja not_active Expired - Fee Related
- 2008-06-26 AU AU2008357111A patent/AU2008357111B2/en not_active Ceased
- 2008-06-26 PL PL08807218T patent/PL2303838T3/pl unknown
- 2008-06-26 CA CA2729035A patent/CA2729035C/en not_active Expired - Fee Related
- 2008-06-26 HR HRP20140194AT patent/HRP20140194T1/hr unknown
- 2008-06-26 PT PT88072186T patent/PT2303838E/pt unknown
- 2008-06-26 WO PCT/IB2008/002665 patent/WO2009144527A1/en not_active Ceased
- 2008-06-26 DK DK08807218.6T patent/DK2303838T3/en active
- 2008-06-26 BR BRPI0822909A patent/BRPI0822909B8/pt active IP Right Grant
- 2008-06-26 CN CN200880130084.3A patent/CN102159539B/zh active Active
- 2008-06-26 MX MX2011000135A patent/MX2011000135A/es active IP Right Grant
- 2008-06-26 ES ES08807218.6T patent/ES2450148T3/es active Active
- 2008-06-26 EP EP08807218.6A patent/EP2303838B1/en not_active Not-in-force
- 2008-06-26 KR KR1020117000071A patent/KR101522066B1/ko not_active Expired - Fee Related
-
2009
- 2009-06-25 CL CL2009001484A patent/CL2009001484A1/es unknown
- 2009-06-25 JO JO2009233A patent/JO2884B1/en active
- 2009-06-25 PE PE2009000908A patent/PE20100257A1/es active IP Right Grant
- 2009-06-26 UY UY0001031945A patent/UY31945A/es not_active Application Discontinuation
- 2009-06-26 AR ARP090102388A patent/AR074159A1/es unknown
-
2010
- 2010-12-23 NI NI201000234A patent/NI201000234A/es unknown
- 2010-12-24 US US12/928,985 patent/US8703183B2/en not_active Ceased
- 2010-12-24 EC EC2010010719A patent/ECSP10010719A/es unknown
- 2010-12-27 TN TNP2010000604A patent/TN2010000604A1/fr unknown
- 2010-12-27 MA MA33460A patent/MA32418B1/fr unknown
- 2010-12-27 TN TNP2010000607A patent/TN2010000607A1/fr unknown
-
2014
- 2014-02-25 CY CY20141100150T patent/CY1115098T1/el unknown
-
2016
- 2016-04-21 US US15/135,018 patent/USRE46496E1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074159A1 (es) | Una sal de glicinato de metformina para el control de glucosa en la sangre, proceso para su obtencion y su uso | |
| ES2656239T3 (es) | Método de preparación de la forma cristalina I del racemato de 4-hidroxido-2-oxo-1-pirrolidina-acetamida | |
| ES2706532T3 (es) | Procedimiento cíclico para producir taurina | |
| PE20081390A1 (es) | Procedimiento para producir derivados de amina opticamente activos | |
| CA2879583C (en) | Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof | |
| CN106317186B (zh) | 环组氨酰-kak，其合成，血栓相关活性及应用 | |
| CN104558035A (zh) | 一种替诺福韦前药的纯化方法 | |
| PAUL et al. | Some side reactions of nitro-L-arginine | |
| PE20210967A1 (es) | Proceso de tratamiento de agua de alta eficiencia | |
| CN104649920B (zh) | 一种门冬氨酸鸟氨酸的制备方法 | |
| CN104016961B (zh) | 一种瑞舒伐他汀钙中间体的制备方法 | |
| ES2992209T3 (es) | Método de preparación de un cristal de heptahidrato de 5'-guanilato disódico | |
| ES2936260T3 (es) | Mejoras en o relacionadas con compuestos orgánicos | |
| DE60104481D1 (de) | Herstellung von Milchsäure durch Verdampfungs-Kristallisationsverfahren | |
| BR102020011608A2 (pt) | Processo de produção de n-acetil taurinato de magnésio e seu produto obtido | |
| DOP2010000403A (es) | Una nueva sal de glicinato de metformina para el control de la glucosa en sangre | |
| CO6331332A2 (es) | Una nueva sal de glicinato de metformina para el control de glucosa en sangre | |
| JPS6152812B2 (es) | ||
| CN108752224A (zh) | 一种醋酸赖氨酸原料药的制备方法 | |
| ES2351882T3 (es) | Procedimiento para la preparación de la pregabalina y de las sales de la misma. | |
| SV2010003780A (es) | Una nueva sal de glicinato de metformina para el control de la glucosa en sangre | |
| CN104177271A (zh) | 一种氯化乙酰左卡尼汀的制备方法 | |
| ATE412654T1 (de) | Verfahren zur herstellung reiner stereoisomeren von tetrahydrofolsäureestersalzen und tetrahydrofolsäure durch fraktionierte kristallisation von tetrahydrofolsäureestersalzen | |
| AR002510A1 (es) | Un procedimiento para la preparacion de derivados de 1-(3-trialquilsilil- fenil)-2,2,2-trifluorometiletanona que son utiles en el tratamiento de laenfermedad de alzheimer y demencia senil y procedimiento para la purificacion de dicho derivado con dicho procedimiento de preparacion. | |
| JP2003096039A (ja) | 高純度ｎ−長鎖アシルアミノ酸塩の製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |